ResMed Q1 Adj. EPS $1.64 Beats $1.62 Est., Revenue $1.10B Beats $1.099B Est.
Portfolio Pulse from Benzinga Newsdesk
ResMed reported Q1 adjusted EPS of $1.64, beating estimates of $1.62. The company's revenue was $1.10B, also surpassing the estimate of $1.099B.
October 26, 2023 | 8:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ResMed's Q1 earnings and revenue beat estimates, which could positively impact the company's stock in the short term.
ResMed's earnings and revenue for Q1 exceeded estimates, which is generally seen as a positive sign by investors and could lead to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100